Effective April 23, 2026, a dozen peptides including BPC-157, TB-500, Semax, and GHK-Cu are no longer on the FDA's restricted Category 2 compounding list. Here's the full picture of what changed, what didn't, and what comes next.
The FDA's compounding framework distinguishes between substances that pharmacies can legally compound and those they cannot. For 503A compounding pharmacies (traditional pharmacies compounding medications for individual patients with a valid prescription), the key lists are:
| Category | What It Means | Compounding Status |
|---|---|---|
| 503A Bulks List (Category 1) | Substances evaluated and approved for use in compounding by licensed 503A pharmacies | ✓ Compounding permitted with Rx |
| Category 2 | Substances nominated for compounding consideration but found to raise significant safety concerns or lack adequate evidence — restricted from compounding | ✗ Compounding prohibited |
| Neither list (gray zone) | Substances not formally evaluated — may or may not be compounded depending on enforcement discretion and other factors | ⚠ Uncertain — case-by-case |
Prior to April 23, 2026, the 12 peptides covered in this guide were on Category 2 — meaning 503A pharmacies were prohibited from compounding them. The April 23 removal takes them off that restricted list, moving them into the gray zone while the PCAC review process proceeds.
The path to this change began with pressure from HHS Secretary Robert F. Kennedy Jr., who in February 2026 publicly called for expanded compounding access for peptides. The key mechanism was straightforward: the 12 peptides had originally been placed on Category 2 based on nominations from interested parties (companies or individuals who submitted them for FDA review). Those original nominators subsequently withdrew their nominations — and with no active nomination, the FDA removed the substances from Category 2, effective April 23, 2026.
Important nuance: The withdrawal of nominations and resulting removal from Category 2 does not mean the FDA has affirmatively determined these peptides are safe for compounding. It means the specific Category 2 restriction — based on those nominations — no longer applies. The July 2026 PCAC meeting will evaluate whether these peptides should be positively authorized for 503A compounding by being added to the Bulk Drug Substances list.
| Peptide | Primary Research Area | Status on This Site | Prior Status |
|---|---|---|---|
| BPC-157 | Tissue repair, gut health, injury recovery, anti-inflammatory | Price page live | Category 2 → Removed |
| TB-500 (Thymosin β4 fragment) | Muscle recovery, wound healing, anti-inflammatory | Price page live | Category 2 → Removed |
| Epitalon | Telomere extension, longevity, anti-aging research | Price page live | Category 2 → Removed |
| GHK-Cu (injectable) | Collagen synthesis, wound healing, skin regeneration, anti-inflammatory | Price page live | Category 2 → Removed |
| Semax | Cognitive enhancement, neuroprotection, BDNF stimulation | Price page live | Category 2 → Removed |
| LL-37 | Antimicrobial defense, immune modulation, wound healing | New page added | Category 2 → Removed |
| DiHexa | Cognitive enhancement, BDNF potentiation, neuroprotection | New page added | Category 2 → Removed |
| DSIP | Sleep regulation, stress response, delta sleep induction | New page added | Category 2 → Removed |
| KPV | Anti-inflammatory, gut health, IBD/Crohn's research | New page added | Category 2 → Removed |
| PEG-MGF | Muscle repair, satellite cell activation, post-exercise recovery | New page added | Category 2 → Removed |
| Melanotan II | Melanogenesis, UV protection research, sexual function | New page added | Category 2 → Removed |
| MOTS-C | Mitochondrial function, metabolic health, insulin sensitivity, longevity | New page added | Category 2 → Removed |
Effective date of the removal. The 12 peptides are no longer on the Category 2 prohibited list.
FDA docket FDA-2025-N-6895 is open for public comment on whether these peptides should be added to the 503A Bulks List. Researchers, clinicians, and the public can submit comments.
The FDA's Pharmacy Compounding Advisory Committee will meet publicly to evaluate the 12 peptides and make recommendations on whether each should be added to the 503A Bulk Drug Substances list. Each peptide will be evaluated individually — some may be recommended, others may not.
Following the PCAC meeting, the FDA will make a final determination for each peptide. Those added to the 503A Bulks List can then be compounded by licensed 503A pharmacies with a valid patient prescription.
The FDA has committed to a second PCAC meeting before the end of February 2027 to continue evaluating the peptide landscape.
The April 2026 reclassification is reshaping the research peptide market significantly. Currently active suppliers include Swiss Chems, Limitless Biotech, Core Peptides, Spectrum Peptides, and others. Pricing on the newly reclassified peptides is evolving as the market adjusts to the regulatory change — expect increased availability and potentially more competitive pricing as the July PCAC meeting approaches and compounding pharmacies prepare to enter the market.
| Situation | What to Do |
|---|---|
| Currently purchasing from research suppliers | Continue as before — research supplier market is unchanged. Verify your supplier is active and has current COAs from an independent laboratory. |
| Interested in prescription compounding access | Monitor the July 23–24, 2026 PCAC meeting outcomes. If PCAC recommends 503A authorization, licensed compounding pharmacies may be able to dispense with a prescription by late 2026. |
| Working with a prescribing physician | Your prescriber can now discuss these peptides with greater regulatory clarity. While 503A compounding isn't yet authorized, the landscape has meaningfully improved. |
| Concerned about supplier quality | Always verify third-party Certificates of Analysis (COAs) from independent labs. The reclassification affects regulatory status, not synthesis quality — quality verification remains essential. |
This page is for informational purposes only and does not constitute legal, medical, or regulatory advice. Regulatory status of peptides is subject to rapid change — always verify current status with the FDA, a licensed compounding pharmacist, or a qualified healthcare attorney. Sources: FDA docket FDA-2025-N-6895; Orrick LLP regulatory update April 2026; SSRP Institute; BioPharma Dive. Updated May 2, 2026.